This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Garattini L, Freemantle N. Comment on: “value-based pricing alternatives for personalised drugs: implications of asymmetric information and competition”. Appl Health Econ Health Policy. 2020.
Levaggi R, Pertile P. Value-based pricing alternatives for personalised drugs: implications of asymmetric information and competition. Appl Health Econ Health Policy. 2019. https://doi.org/10.1007/s40258-019-00541-z.
Lakdawalla DN. Economics of the Pharmaceutical Industry. J Econ Lit. 2018;56:397–449.
World Health Organization. Pricing cancer medicine and its impacts. World Health Organzation; 2018.
Vogler S, Paris V, Ferrario A, Wirtz VJ, de Joncheere K, Schneider P, et al. How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries. Appl Health Econ Health Policy. 2017;15:307–21.
Garattini L, Padula A. Pharmaceutical pricing conundrum: time to get rid of it? Eur J Health Econ. 2018;19:1035–8.
Katz A. Pharmaceutical lemons: innovation and regulation in the drug industry. Mich Telecommun Technol Law Rev. 2007;14:1–41.
Prasad V, Mailankody S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med. 2017;177:1569–75.
The authors have not receive any specific funding for the research.
Conflict of interest
The authors have no conflict of interest to declare.
About this article
Cite this article
Levaggi, R., Pertile, P. Authors’ Reply to Garattini and Freemantle: “Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition”. Appl Health Econ Health Policy 18, 455–456 (2020). https://doi.org/10.1007/s40258-020-00557-w